SLN · Nasdaq, OTC · CIK 0001479615

Silence Therapeutics plc

Silence Therapeutics plc’s most recent SEC filing in our snapshot is a Form DEFA14A filed on Oct 19, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $559.0K and net income of -$88.6M, according to its XBRL data on EDGAR. Its EDGAR record lists 10 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$559.0K
Net income, FY2025
-$88.6M
Form 4 filings on record, past 12 months
10

Company overview

Legal name (as filed)
Silence Therapeutics plc
Tickers
SLN, SLNCF
SEC Central Index Key (CIK)
0001479615
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
LONDON
State or country of incorporation
United Kingdom
Fiscal year ends
—
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2301 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Silence Therapeutics plc’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$12.4MFY2021$21.7MFY2022$31.6MFY2023$43.3MFY2024$559.0KFY2025
Net income
n/aFY2021-$50.3MFY2022-$54.2MFY2023-$45.3MFY2024-$88.6MFY2025
SLN annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$12.4M$21.7M$31.6M$43.3M$559.0K
Net income—-$50.3M-$54.2M-$45.3M-$88.6M
Diluted EPS—-$0.52-$0.49-$0.33-$0.63
Total assets——$119.4M$202.6M$131.4M
Cash and equivalents$73.5M$42.0M$68.8M$121.3M$11.3M

XBRL tags used: revenue = RevenueFromContractsWithCustomers; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SLN latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 5, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 19, 20268-KMaterial agreement; Regulation FD disclosure· period Oct 18, 2026Document · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Jun 16, 2026Document · Index
Mar 13, 202420-FAnnual report of a foreign private issuer· period Dec 31, 2023Document · Index
Dec 9, 20246-KReport of a foreign private issuer· period Dec 9, 2024Document · Index

Recent SEC filings

The 40 newest documents filed by or about Silence Therapeutics plc, by form type:

8-K ×104 ×6SCHEDULE 13G/A ×3424B5 ×3DEFA14A ×2SCHEDULE 13D/A ×210-Q ×2UPLOAD ×2SCHEDULE 13G ×1S-3MEF ×18-K/A ×1EFFECT ×1CORRESP ×1S-3 ×1ARS ×1DEF 14A ×1S-8 ×110-K ×1
SLN recent filings
FiledFormWhat it isOriginal
Oct 19, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Oct 19, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Oct 19, 20268-KMaterial agreement; Regulation FD disclosure· period Oct 18, 2026Document · Index
Oct 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 13, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 13, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Aug 13, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20268-KMaterial agreement; Other events· period Aug 10, 2026Document · Index
Aug 12, 2026424B5424B5Document · Index
Aug 11, 2026S-3MEFS-3MEFDocument · Index
Aug 10, 2026424B5424B5Document · Index
Aug 10, 20268-KRegulation FD disclosure; Other events· period Aug 10, 2026Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 10, 20268-KResults of operations· period Aug 10, 2026Document · Index
Jul 16, 20268-K/ADirector or officer change· period Jul 10, 2026Document · Index
Jul 8, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jul 7, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 29, 2026Document · Index
Jun 23, 20268-KRegulation FD disclosure· period Jun 23, 2026Document · Index
Jun 16, 20268-KShareholder vote results· period Jun 16, 2026Document · Index
Jun 11, 20268-KOther events· period Jun 11, 2026Document · Index
May 27, 2026EFFECTEFFECTDocument · Index
May 27, 2026424B5424B5Document · Index
May 22, 2026CORRESPCORRESPDocument · Index
May 22, 2026UPLOADUPLOADDocument · Index
May 18, 20268-KMaterial agreement; Agreement terminated; Other events· period May 18, 2026Document · Index
May 18, 2026S-3Simplified registration statementDocument · Index
May 7, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 7, 20268-KResults of operations· period May 7, 2026Document · Index
Apr 29, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Jun 16, 2026Document · Index
Mar 5, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Mar 5, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 5, 20268-KResults of operations; Regulation FD disclosure· period Mar 5, 2026Document · Index
Feb 13, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 3, 2025Document · Index
Feb 9, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 9, 2026UPLOADUPLOADDocument · Index
Jan 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index

Insider filing activity

10 Form 4 filings appear in Silence Therapeutics plc’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001479615 and XBRL company facts. Silence Therapeutics plc on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.